The increasing need for early cancer detection and improved diagnostic accuracy is accelerating innovation in cancer diagnostic tests, endoscopic cancer diagnosis, and molecular cancer diagnostics. Gastric cancer remains a significant healthcare concern, requiring advanced technologies that enable early identification, accurate staging, and personalized treatment planning. The growing adoption of advanced diagnostic platforms is strengthening the expansion of the U.S. Gastric Cancer Diagnostics Market, supported by technological advancements, increasing awareness, and rising demand for precision oncology solutions.

The U.S. gastric cancer diagnostics market size was valued at USD 492.83 million in 2025 and is projected to grow at a CAGR of 7.4% from 2026 to 2034. The market is expected to expand from USD 529.00 million in 2026 to USD 938.38 million by 2034, driven by advancements in cancer detection technologies, rising demand for early diagnosis, and increasing adoption of molecular diagnostic solutions.

Rising Importance of Cancer Diagnostic Tests

Cancer diagnostic tests play a critical role in identifying malignant cells, determining cancer progression, and guiding effective treatment decisions. In gastric cancer management, diagnostic approaches include imaging techniques, laboratory testing, biopsies, and advanced molecular analysis.

Early detection significantly improves treatment outcomes by allowing physicians to identify tumors at earlier stages when therapeutic interventions are more effective. Traditional diagnostic methods such as histopathology and biopsy analysis continue to serve as essential tools, while newer technologies are improving speed, accuracy, and disease characterization.

The increasing prevalence of gastric cancer and the growing focus on preventive healthcare are driving demand for reliable diagnostic solutions. Healthcare providers are adopting advanced testing methods to improve screening efficiency and support better clinical decision-making.

Role of Endoscopic Cancer Diagnosis in Gastric Cancer Detection

Endoscopic cancer diagnosis remains one of the most widely used approaches for detecting gastric abnormalities. Endoscopy allows physicians to directly visualize the stomach lining and identify suspicious lesions, ulcers, or abnormal tissue changes.

Advanced endoscopic technologies, including high-definition imaging, narrow-band imaging, and enhanced visualization systems, are improving the ability of clinicians to detect early-stage gastric cancer. These innovations provide clearer images of tissue structures and support more accurate biopsy collection.

Key benefits of endoscopic cancer diagnosis include:

• Direct visualization of gastric abnormalities
• Accurate tissue sampling through biopsy
• Early detection of precancerous changes
• Improved disease monitoring
• Better treatment planning

The increasing integration of advanced endoscopy systems is contributing to the growth of the U.S. Gastric Cancer Diagnostics Market. The instruments segment is expected to experience strong growth due to increased adoption of advanced endoscopy systems, liquid biopsy platforms, and next-generation sequencing technologies.

Growth of Molecular Cancer Diagnostics

The emergence of molecular cancer diagnostics is transforming gastric cancer detection by enabling physicians to analyze genetic, genomic, and molecular characteristics of tumors. These technologies support precision medicine by identifying specific biomarkers associated with disease development and treatment response.

Molecular diagnostic techniques include:

• Next-generation sequencing (NGS)
• Polymerase chain reaction (PCR) testing
• Biomarker analysis
• Genetic profiling
• Liquid biopsy testing

Unlike conventional diagnostic methods, molecular cancer diagnostics provide deeper insights into tumor biology. This information helps healthcare professionals select targeted therapies and develop personalized treatment strategies.

The growing adoption of genomic testing and biomarker-based approaches is expected to create significant opportunities within the gastric cancer diagnostics landscape. Diagnostic laboratories are increasingly expanding molecular testing capabilities to meet the rising demand for advanced cancer evaluation.

Technological Advancements Supporting Market Expansion

Innovation in healthcare technology is one of the primary factors driving growth in the U.S. Gastric Cancer Diagnostics Market. Artificial intelligence (AI), digital pathology, automation, and advanced imaging technologies are enhancing diagnostic accuracy and reducing turnaround times.

AI-powered diagnostic systems can analyze medical images, identify suspicious patterns, and assist pathologists in evaluating tissue samples. Digital pathology platforms enable remote analysis and collaboration among specialists, improving access to expert diagnostics.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/us-gastric-cancer-diagnostics-market

Key Players

• Abbott Laboratories
• Agilent Technologies, Inc.
• Becton, Dickinson and Company (BD)
• Bio-Rad Laboratories, Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• GE HealthCare
• Illumina, Inc.
• Mirxes Pte Ltd
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Market Drivers and Opportunities

Several factors are contributing to the continued expansion of the U.S. gastric cancer diagnostics sector:

• Increasing awareness about early cancer detection
• Rising adoption of advanced diagnostic technologies
• Growing demand for personalized medicine
• Expansion of molecular testing capabilities
• Increasing healthcare investments in oncology diagnostics
• Growth of diagnostic laboratories and specialized cancer centers

The reagents and consumables segment accounted for the largest share of the market in 2025, supported by continuous demand for staining solutions, molecular testing kits, and other diagnostic materials used in cancer testing procedures.

Future Outlook

The future of gastric cancer diagnosis will be shaped by continuous innovation in cancer diagnostic tests, endoscopic cancer diagnosis, and molecular cancer diagnostics. As healthcare moves toward precision medicine, advanced diagnostic technologies will play a central role in improving early detection and treatment outcomes.

The integration of AI, genomic analysis, and minimally invasive testing methods is expected to further transform gastric cancer management. With increasing demand for accurate, personalized, and efficient diagnostic solutions, the U.S. Gastric Cancer Diagnostics Market is positioned for sustained growth through 2034.

More Trending Latest Reports By Polaris Market Research:

Proteinase K Market

Veterinary Active Pharmaceutical Ingredients Manufacturing Market

High Level Disinfection Services Market

Breast Implants Market

Hospital Acquired Infection Therapeutics Market

Gene Expression Analysis Market

Next generation Sequencing Sample Preparation Market

Lysosomal storage disease treatment market